Collegium Pharmaceutical, Inc. Repayments of Long-Term Debt
Collegium Pharmaceutical, Inc. (COLL) reported Repayments of Long-Term Debt of $11.50 million for the 12-month period ending 2020-12-31, per its 10-K filed 2023-02-23.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2023-02-23
- Collegium Pharmaceutical, Inc. repayments of long-term debt for the quarter ending 2020-12-31 was $0.00.
- Collegium Pharmaceutical, Inc. repayments of long-term debt for the quarter ending 2020-09-30 was $0.00.
- Collegium Pharmaceutical, Inc. repayments of long-term debt for the quarter ending 2020-06-30 was $0.00.
- Collegium Pharmaceutical, Inc. repayments of long-term debt for the quarter ending 2020-03-31 was $11.50M.
- Collegium Pharmaceutical, Inc. repayments of long-term debt for fiscal 2020 was $11.50M.
- Collegium Pharmaceutical, Inc. repayments of long-term debt for fiscal 2017 was $2.67M, a 0.00% change from fiscal 2016.
- Collegium Pharmaceutical, Inc. repayments of long-term debt for fiscal 2016 was $2.67M, a 107.39% increase from fiscal 2015.
- Collegium Pharmaceutical, Inc. repayments of long-term debt for fiscal 2015 was $1.29M.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $0.00 derived: sum of 2 quarters · filed 2023-02-23 | $0.00 derived: sum of 3 quarters · filed 2023-02-23 | $11.50M 10-K · filed 2023-02-23 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $11.50M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $11.50M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $11.50M 10-Q · filed 2021-05-06 | |||
| 2017-12-31 | $667.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $1.33M derived: sum of 2 quarters · filed 2020-02-27 | $2.00M derived: sum of 3 quarters · filed 2020-02-27 | $2.67M 10-K · filed 2020-02-27 |
| 2017-09-30 | $667.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $1.33M derived: sum of 2 quarters · filed 2018-11-08 | $2.00M 10-Q · filed 2018-11-08 | $2.67M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | $667.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $1.33M 10-Q · filed 2018-08-08 | $2.00M derived: sum of 3 quarters · filed 2019-02-27 | $2.67M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | $666.00K 10-Q · filed 2018-05-09 | $1.33M derived: sum of 2 quarters · filed 2019-02-27 | $2.00M derived: sum of 3 quarters · filed 2019-02-27 | $2.67M derived: sum of 4 quarters · filed 2019-02-27 |
| 2016-12-31 | $667.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $1.33M derived: sum of 2 quarters · filed 2019-02-27 | $2.00M derived: sum of 3 quarters · filed 2019-02-27 | $2.67M 10-K · filed 2019-02-27 |
| 2016-09-30 | $667.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $1.33M derived: sum of 2 quarters · filed 2017-11-08 | $2.00M 10-Q · filed 2017-11-08 | |
| 2016-06-30 | $666.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $1.33M 10-Q · filed 2017-08-09 | ||
| 2016-03-31 | $667.00K 10-Q · filed 2017-05-10 | |||
| 2015-12-31 | $1.29M 10-K · filed 2018-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |